- Home
- RNAZ vs VYNE Comparison
RNAZ vs VYNE Comparison
Compare RNAZ & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- VYNE
- Stock Information
- Founded
- RNAZ 2016
- VYNE 2003
- Country
- RNAZ United States
- VYNE United States
- Employees
- RNAZ N/A
- VYNE N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- VYNE Health Care
- Exchange
- RNAZ Nasdaq
- VYNE Nasdaq
- Market Cap
- RNAZ 8.7M
- VYNE 9.6M
- IPO Year
- RNAZ 2021
- VYNE 2018
- Fundamental
- Price
- RNAZ $8.60
- VYNE $0.37
- Analyst Decision
- RNAZ Strong Buy
- VYNE Buy
- Analyst Count
- RNAZ 1
- VYNE 2
- Target Price
- RNAZ $280.00
- VYNE $8.00
- AVG Volume (30 Days)
- RNAZ 19.3K
- VYNE 1.7M
- Earning Date
- RNAZ 11-14-2025
- VYNE 11-06-2025
- Dividend Yield
- RNAZ N/A
- VYNE N/A
- EPS Growth
- RNAZ N/A
- VYNE N/A
- EPS
- RNAZ N/A
- VYNE N/A
- Revenue
- RNAZ N/A
- VYNE $524,000.00
- Revenue This Year
- RNAZ N/A
- VYNE N/A
- Revenue Next Year
- RNAZ N/A
- VYNE N/A
- P/E Ratio
- RNAZ N/A
- VYNE N/A
- Revenue Growth
- RNAZ N/A
- VYNE 6.29
- 52 Week Low
- RNAZ $6.15
- VYNE $0.28
- 52 Week High
- RNAZ $468.44
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- RNAZ 34.45
- VYNE 52.86
- Support Level
- RNAZ $8.41
- VYNE $0.35
- Resistance Level
- RNAZ $9.85
- VYNE $0.38
- Average True Range (ATR)
- RNAZ 0.68
- VYNE 0.03
- MACD
- RNAZ -0.30
- VYNE 0.00
- Stochastic Oscillator
- RNAZ 11.05
- VYNE 72.87
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.